KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized,
double-blind, placebo-controlled period ("Randomized Period"), followed by an 8-week
open-label safety extension period, where all subjects receive KRX-0502 (ferric citrate)
("Extension Period").